跳至主要内容
临床试验/JPRN-jRCT1090220183
JPRN-jRCT1090220183已完成Unknown

Clinical study about the hypotensive effect and the inhibitory effect on the elevatin of uric acid level irbesartan and trichlormethiazide in the essential hypertension patients

agoya Medical Association0 个研究点目标入组 100 人开始时间: 2014年6月25日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • Essential hypertensive patients who have been taking ARB except irbesartan (IrbetanR) and losartan and concomitantly with trichlormethiazide (FluitranR) 1 mg, and have not changed these medications at least for 8 weeks,
  • whose systolic blood pressure (BP) or diastolic BP at baseline is >=130 or >=80 mmHg respectively and also who signed on informed consent to participate in this study.

排除标准

  • Patients with severe hypertension (diastolic BP >=120 mmHg), secondary or malignant hypertension. Patients with recent history of myocardial infarction or stroke within 6 months.
  • Patients with severe hepatic dysfunction (AST >=100 IU/L or ALT >=100 IU/L or bilirubin >=2.5 mg/dL),or with renal dysfunction (serum creatinine >=2.0 mg/dL or e-GFR<30 mL/min/1.73 m2), or type 1 diabetes mellitus, or poorly controlled type 2 diabetes mellitus.
  • Patients with drug or alcohol abuse. Patients who are pregnant or breastfeeding.
  • Patients under participation in other clinical trials.
  • Patients with history of hypersensitivity to irbesartan (IrbetanR) and trichlormethiazide (FluitranR)
  • Patients who took some concomitant drugs prohibited during the previous 8 weeks before the start of study.
  • Patients who are deemed ineligible by investigator.

研究者

发起方
agoya Medical Association

相似试验

Clinical study about the hypotensive effect and the... | 临床试验